Posts

U.S. drugmaker Pfizer Inc and its German partner BioNTech SE said on Friday their Omicron-tailored shot targeting the BA.4/5 subvariants produced a strong antibody response in humans than the original shot after one month.

German Chancellor Olaf Scholz announced an agreement on Friday to let expatriates in China use the COVID-19 vaccine from Germany’s BioNTech and pressed for Beijing to allow the shot to be made freely available to Chinese citizens.

The early-stage study, which is being sponsored by BioNTech, aims to evaluate the combination shot’s safety, tolerability and immunogenicity, or the ability to generate immune response.

Swiss drugs regulator Swissmedic said it had been informed by vaccination centers of the appearance of bubbles during the preparation of the updated vaccine from Pfizer and BioNTech targeting the original version of the coronavirus and the BA.1 Omicron variant that led to a record surge in cases last winter.

Swiss drugs regulator Swissmedic said on Wednesday it is examining potential risks in connection with bubbles that appeared in vials of COVID-19 vaccine boosters retooled to target the Omicron variant of the coronavirus.

Reports of heavy periods – bleeding characterized by increased volume and/or duration that interferes with the quality of life – have been observed during clinical trials, from cases in the real world and in medical literature, according to the European Medicines Agency.

Pfizer Inc. expects to roughly quadruple the price of its COVID-19 vaccine to about $110 to $130 per dose after the United States government’s current purchase program expires, Pfizer executive Angela Lukin said on Thursday.

With most Americans delaying or skipping new COVID-19 booster shots, analysts and investors are now predicting far fewer will be given each year, pushing the number of shots well below annual flu vaccinations.

Pfizer and its German partner BioNTech said their COVID-19 vaccine booster, adapted for the BA.4 and the BA.5 subvariants, generated a strong immune response and was well tolerated in testing on humans.

The Moderna COVID-19 Vaccine, Bivalent is authorized for administration at least two months following completion of primary or booster vaccination in children down to six years of age. The Pfizer-BioNTech COVID-19 Vaccine, Bivalent is authorized for administration at least two months following completion of primary or booster vaccination in children down to five years of age.